University of Minnesota
MICaB Graduate Program
MICaB Home | U of M Medical School | Graduate School

Unit's home page.

MICaB Faculty

Marco Pravetoni, Ph.D.

Associate Professor

Departments of Medicine and Pharmacology

University of Minnesota, 2008, Ph.D.

612-873-6856 office

Research Interests:

Vaccine development, B and CD4+ T cell responses to vaccines

The Pravetoni lab focuses on the development of vaccines for treatment of substance abuse disorders, such as abuse of heroin, prescription opioids, and stimulants. Research projects include: vaccine development in pre-clinical models of drug addiction, characterization of candidate vaccine formulations for clinical evaluation, dissecting T cell-dependent B cell mechanisms underlying generation of effective anti-drug antibodies to guide rational design of next-generation vaccines, and strategies to enhance vaccine efficacy by programming vaccine-specific B and CD4+ T cell differentiation toward germinal center formation by means of adjuvants, immunomodulators, and delivery platforms. Future efforts will apply these approaches to other vaccines against emerging pathogens, biodefense targets, or chemical warfare.

Selected Recent Publications:

•Laudenbach M, Tucker AM, Runyon SP, Carroll FI, and Pravetoni M. 2015. The frequency of early-activated hapten-specific B cell subsets correlates with efficacy of vaccines for nicotine dependence. Vaccine. Nov 17;33(46):6332-9.
Laudenbach M, Baruffaldi F, Vervacke J, Distefano M, Titcombe P, Mueller DL, Tubo NJ, Griffith TS and Pravetoni M. 2015. Frequency of the naïve and activated hapten-specific B cell populations dictates conjugate vaccine efficacy against oxycodone. J. Immunol. Jun 15;194(12):5926-36.
•Kotecki L, Hearing M, McCall N, Fernandez de Velasco EM, Pravetoni M, Arora D, Victoria N, Munoz M, Xia Z, Slesinger P, Weaver CD, and Wickman K. 2015. GIRK channels modulate opioid-induced motor activity in a cell type- and subunit-dependent manner". J Neurosci. May 6;35(18):7131-42.
M Pravetoni, PR Pentel, DN Potter, EH Chartoff, L Tally, and MG Lesage .2014. Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. PLoS One. Jul 15;9(7):e101807.
Pravetoni M, Vervacke J, Distefano M, Tucker AM, Laundenbach M and Pentel PR. 2014. Effect of clinically-approved carriers and adjuvants on the pre-clinical efficacy of a vaccine against oxycodone in mice and rats. PLoS One. 2014 May 5;9(5):e96547.
•Taylor JJ, Laudenbach M, Tucker AM, Jenkins MK and Pravetoni M. 2014. Naïve B cells are biomarkers of vaccine efficacy against drugs of abuse. J. Immunological Methods, Mar; 405:74-86.

For comprehensive list of publications, refer to Pubmed: Pravetoni M